At the news
? NEUTRALIMPACT 5/10 8-K filed Aug 13, 2026 at 07:30 ET
Indaptus Therapeutics reported Q2 2026 results with no active clinical programs, having discontinued its Decoy20 study. Net loss narrowed to $1.8M from $5.2M YoY, driven by cost cuts. The company raised $12M in a June private placement, boosting cash to ~$11.6M, but is now a cash-burning shell evaluating strategic alternatives, including potential acquisitions or investments in new research areas like neurological disorders. The stock is a speculative story on the company's ability to execute a pivot, with no pipeline value.
- Net loss for Q2 2026 was $1.8M, down from $5.2M in Q2 2025.
- Cash, cash equivalents, and short-term investments totaled $11.6M as of June 30, 2026.
- Completed a $12.0M private placement on June 17, 2026, issuing 20M shares at $0.60/share.
- Discontinued further enrollment in the Decoy20 combination study; no active clinical development programs.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access